Form 4: AN2 Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
AN2 Therapeutics' Chief Operating and Legal Officer, Joshua M. Eizen, sold 9,663 shares of common stock to cover tax obligations following the vesting of restricted stock units.
Summary
- Joshua M. Eizen, the Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, sold 9,663 shares of common stock on January 3, 2025, at a price of $1.341 per share.
- This sale was conducted to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
- Following the transaction, Eizen beneficially owns 116,672 shares of AN2 Therapeutics common stock.
- The reported holdings include 31,500 RSUs vesting over four years from November 4, 2024, 22,500 RSUs vesting over three years from January 1, 2025, and 45,000 RSUs vesting in two tranches on January 1, 2026 and July 1, 2026.
Sentiment
Score: 5
Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a standard practice among executives who receive equity compensation.
- Many companies use RSUs as part of their compensation packages, and the vesting schedules and tax implications are generally similar across the industry.
- The amount of shares sold is relatively small compared to the total holdings, which is typical for these types of transactions.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Restricted Stock Units (RSUs) vested, triggering tax obligations. |
| 01/03/2025 | Date of the sale of 9,663 shares of common stock by Joshua M. Eizen. |
| 01/07/2025 | Date the Form 4 was signed. |
| 11/04/2024 | Start date for vesting of 31,500 RSUs. |
Keywords
AN2 Therapeutics, ANTX, Form 4, insider trading, Joshua M. Eizen, restricted stock units, RSU, tax obligations, share sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.